PMID- 25175689
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20191027
IS  - 1875-5992 (Electronic)
IS  - 1871-5206 (Linking)
VI  - 14
IP  - 8
DP  - 2014
TI  - HLA-I antigen presentation and tapasin influence immune responses against 
      malignant brain tumors - considerations for successful immunotherapy.
PG  - 1094-100
AB  - Human leukocyte antigen class I (HLA-I) presents antigenic peptides to cytotoxic 
      CD8+ T cells (CTLs). This is a pivotal step in the generation of CTL responses. 
      Both the quantity and quality of peptide-HLA-I (pHLA-I) complexes are crucial for 
      CTL responses, but the level of HLA-I expression per se is also directly involved 
      in dictating NK-cell responses. Antigen processing machinery (APM) proteins are 
      involved in the maturation of HLA-I and in the selection of which peptides are - 
      or are not - presented. Thus, these proteins are key players in shaping the 
      immune response to cells in health and disease. In this review, we recap the most 
      important features of APM components and their synergistic work to assure proper 
      pHLA-I cell surface expression. We pay special attention to the HLA-I dedicated 
      multifunctional protein, tapasin, and in relation to the different 
      tapasin-dependency of HLA-I allomorphs we also discuss allomorph specific traits 
      in maturation, structure and linkage to malignant diseases and brain tumors in 
      particular. We next discuss the possibilities of restoring or manipulating the 
      immune responses against brain tumors. In this context we discuss IFNgamma therapy, 
      cytostatics and irradiation. Finally, we integrate current views and knowledge to 
      set the direction for future emphasis in the area of immunotherapy against brain 
      tumors.
FAU - Darabi, Anna
AU  - Darabi A
FAU - Thuring, Camilla
AU  - Thuring C
FAU - Paulsson, Kajsa M
AU  - Paulsson KM
AD  - Lund University, BMC D14 Immunology, Tornavagen 10, 221 84 Lund, Sweden. 
      Kajsa_M.Paulsson@med.lu.se.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Anticancer Agents Med Chem
JT  - Anti-cancer agents in medicinal chemistry
JID - 101265649
RN  - 0 (Cytostatic Agents)
RN  - 0 (HLA Antigens)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (tapasin)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antigen Presentation
MH  - Brain Neoplasms/immunology/radiotherapy/*therapy
MH  - Cytostatic Agents/therapeutic use
MH  - HLA Antigens/*metabolism
MH  - Humans
MH  - Immunotherapy
MH  - Interferon-gamma/immunology/therapeutic use
MH  - Membrane Transport Proteins/*metabolism
EDAT- 2014/09/02 06:00
MHDA- 2015/05/13 06:00
CRDT- 2014/09/02 06:00
PHST- 2012/09/05 00:00 [received]
PHST- 2012/11/19 00:00 [revised]
PHST- 2013/10/18 00:00 [accepted]
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - ACAMC-EPUB-61892 [pii]
AID - 10.2174/1871520614666140825110001 [doi]
PST - ppublish
SO  - Anticancer Agents Med Chem. 2014;14(8):1094-100. doi: 
      10.2174/1871520614666140825110001.